 Eliem Therapeutics Incs NASDAQ: ELYM ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain DPNP failed to achieve statistically significant separation from placebo on the trials primary endpoint of daily pain score. The Company will longer pursue the. 